Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by pricelesson Feb 27, 2021 8:32am
196 Views
Post# 32678310

RE:RE:MERK BUYS....

RE:RE:MERK BUYS....What is RVX holding in their hand that Oristar decided to convert at $1.08 rather than wait to convert at a much lower diliuted price if rvx was going to do BETONMACE2 on their own. seeing that Oristar is on ther BOD one would think that a deal can't be too far.  Seeing your example of PAND being purchased without a btd and in early stage for 1.9 Billion USD  what is rvx worth with a BTD and being in the  large possibilty of succeeding the phase3 interim analysis and starting drug registration.    I can't see why a CVR type of deal would create a win win or risk versus reward for any BP with the long term revenue potential apabetalone would create over 15 years .     Something does add up.....
<< Previous
Bullboard Posts
Next >>